4-(methylsulfonylmethyl)-3-[(2-morpholin-4-ylacetyl)amino]-N-(5-phenyl-1,3,4-thiadiazol-2-yl)benzamide
C23H25N5O5S2 — CID 90461315
Data last refreshed: (MolForge compound catalog, from PubChem)
About 4-(methylsulfonylmethyl)-3-[(2-morpholin-4-ylacetyl)amino]-N-(5-phenyl-1,3,4-thiadiazol-2-yl)benzamide
4-(methylsulfonylmethyl)-3-[(2-morpholin-4-ylacetyl)amino]-N-(5-phenyl-1,3,4-thiadiazol-2-yl)benzamide (PubChem CID 90461315) has the molecular formula C23H25N5O5S2 and a molecular weight of 515.62 g/mol. Its IUPAC name is 4-(methylsulfonylmethyl)-3-[(2-morpholin-4-ylacetyl)amino]-N-(5-phenyl-1,3,4-thiadiazol-2-yl)benzamide.
Molecular Properties
| Compound Name | 4-(methylsulfonylmethyl)-3-[(2-morpholin-4-ylacetyl)amino]-N-(5-phenyl-1,3,4-thiadiazol-2-yl)benzamide |
|---|---|
| PubChem CID | 90461315 |
| Molecular Formula | C23H25N5O5S2 |
| Molecular Weight | 515.62 g/mol |
| Exact Mass | 515.13 |
| IUPAC Name | 4-(methylsulfonylmethyl)-3-[(2-morpholin-4-ylacetyl)amino]-N-(5-phenyl-1,3,4-thiadiazol-2-yl)benzamide |
| SMILES | CS(=O)(=O)Cc1ccc(C(=O)Nc2nnc(-c3ccccc3)s2)cc1NC(=O)CN1CCOCC1 |
| InChI | InChI=1S/C23H25N5O5S2/c1-35(31,32)15-18-8-7-17(13-19(18)24-20(29)14-28-9-11-33-12-10-28)21(30)25-23-27-26-22(34-23)16-5-3-2-4-6-16/h2-8,13H,9-12,14-15H2,1H3,(H,24,29)(H,25,27,30) |
| InChIKey | LWANVTRQRKFEOL-UHFFFAOYSA-N |
| XLogP | 2.27 |
| TPSA | 130.59 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 35 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 515.62 |
| LogP ≤ 5 | 2.27 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 90461315 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.